According to the latest return for equity issuers submitted to Hong Kong Exchanges and Clearing Limited, the total issued ordinary share capital of SINOMAB BIOSCIENCE LIMITED remained at 1,386,638,336 shares as of 30 November 2025. No shares were issued or cancelled during the reporting month, and there were no movements in treasury shares.

The 2022 Share Option Scheme, approved on 26 October 2022 and amended on 14 June 2024, recorded 69,009,462 outstanding options at the beginning and end of November 2025. No additional shares were issued or transferred from treasury under this scheme, and no funds were raised from any exercise of options.

All other categories of securities, including warrants, convertibles, and other arrangements to issue shares, reported no activity during the period. The company confirmed compliance with relevant listing rules and legal requirements in issuing and handling its securities.